Compare HTZ & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTZ | ANIP |
|---|---|---|
| Founded | 1918 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 1997 | N/A |
| Metric | HTZ | ANIP |
|---|---|---|
| Price | $5.55 | $83.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $5.05 | ★ $107.33 |
| AVG Volume (30 Days) | ★ 5.2M | 503.8K |
| Earning Date | 02-12-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.67 |
| Revenue | ★ $8,516,000,000.00 | $826,880,000.00 |
| Revenue This Year | N/A | $44.35 |
| Revenue Next Year | $3.35 | $11.13 |
| P/E Ratio | ★ N/A | $49.55 |
| Revenue Growth | N/A | ★ 48.87 |
| 52 Week Low | $3.26 | $54.10 |
| 52 Week High | $9.39 | $99.50 |
| Indicator | HTZ | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 51.65 | 49.89 |
| Support Level | $5.33 | $83.03 |
| Resistance Level | $6.14 | $86.97 |
| Average True Range (ATR) | 0.32 | 3.50 |
| MACD | 0.02 | 0.51 |
| Stochastic Oscillator | 36.27 | 63.62 |
Hertz Global Holdings Inc is engaged principally in the business of renting vehicles through Hertz, Dollar and Thrifty brands. The Company has identified two reportable segments: Americas RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in the U.S., Canada, Latin America and the Caribbean; International RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in locations other than the U.S., Canada, Latin America and the Caribbean. The Company maintain a substantial network of company-operated rental locations, a majority of which are in Europe, and have franchisees and partners that operate rental locations under brands. Geographical markets includes U.S., Europe, Pacific Asia, Middle East and Africa, Latin America.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.